May 03 Pharm 9004 Lecture by Bruce A. Littlefield
5/3/2018
[Pinn 5023] Hosted by John Lazo, Beth Sharlow and the Pharm 9004 Spring 2018 Class Bruce A. Littlefield, Ph.D., is a Distinguished Scientist and Head of Translational MedicineGlobal Oncology, Eisai Inc. Dr. Littlefield holds the dual positions of Distinguished Scientist and Head, Translational Medicine in the Global Oncology group at Eisai, a global pharmaceutical company headquartered in Tokyo. A biochemist by training, Dr. Littlefield first joined Eisai in 1990 and since that time has overseen numerous natural product-based oncology drug discovery programs. One such program, initiated at Eisai by Dr. Littlefield in 1992 together with Professor Yoshito Kishi of Harvard, was based on the marine sponge natural product halichondrin B. This program led to development of eribulin (Halaven ® ), currently approved in over 60 countries for treatment of certain patients with advanced breast cancer, with additional approvals for advanced liposarcoma or soft tissue sarcoma in many other countries. Dr. Littlefield has published widely in the cancer research and drug development areas, holds numerous drug-related patents, and is a frequent lecturer at universities, medical centers and scientific conferences in the US and abroad. In addition to working at Eisai, Dr. Littlefield has held faculty positions at both Yale and Harvard Medical Schools, most recently in 2009-2011, when he temporarily moved to Harvard as Scientific Director of a new natural products research program, before returning to Eisai in his current capacity in 2011.
May 03 Pharm 9004 Lecture by Bruce A. Littlefield
5/3/2018
[Pinn 5023] Hosted by John Lazo, Beth Sharlow and the Pharm 9004 Spring 2018 Class Bruce A. Littlefield, Ph.D., is a Distinguished Scientist and Head of Translational MedicineGlobal Oncology, Eisai Inc. Dr. Littlefield holds the dual positions of Distinguished Scientist and Head, Translational Medicine in the Global Oncology group at Eisai, a global pharmaceutical company headquartered in Tokyo. A biochemist by training, Dr. Littlefield first joined Eisai in 1990 and since that time has overseen numerous natural product-based oncology drug discovery programs. One such program, initiated at Eisai by Dr. Littlefield in 1992 together with Professor Yoshito Kishi of Harvard, was based on the marine sponge natural product halichondrin B. This program led to development of eribulin (Halaven ® ), currently approved in over 60 countries for treatment of certain patients with advanced breast cancer, with additional approvals for advanced liposarcoma or soft tissue sarcoma in many other countries. Dr. Littlefield has published widely in the cancer research and drug development areas, holds numerous drug-related patents, and is a frequent lecturer at universities, medical centers and scientific conferences in the US and abroad. In addition to working at Eisai, Dr. Littlefield has held faculty positions at both Yale and Harvard Medical Schools, most recently in 2009-2011, when he temporarily moved to Harvard as Scientific Director of a new natural products research program, before returning to Eisai in his current capacity in 2011.
Apr 26 Pharmacology Seminar by John Huguenard
4/26/2018
[Pinn Hall 1-17] Hosted by Mark Beenhakker, John Haguenard, Phd is a Professor of Neurology and Neurological Sciences, Standford University Lab Summary: We study mechanisms of neural circuit synchronization and oscillation, using a combination of me...
Apr 19 Pharmacology Seminar by Josh Huang
4/19/2018
[Pinn Hall 1-17] Hosted by Julius Zhu; Co-Sponsored by the Brain Institute, Josh Huang, PhD, is a Professor at Cold Spring Harbor Laboratory About Huang's Lab: Cellular basis of neocortex circuit architecture Our goal is to understand the cellular ...
Apr 17 Spike Detection with Engineered Optical Voltage Sensors by Yiyang Gong
4/17/2018
[TBD] Hosted by Julius Zhu, Neurosciences Graduate Program and Pharmacology, Yiyang Gong is an Associate Professor, Biomedical Engineering, Duke University Research Interests: Recording and understanding brain activity by developing novel combinatio...
Apr 12 “A New Locus of Lipolysis Control in Adipose Tissue and Muscle by James Grannerman
4/12/2018
[Pinn Hall 1-17] Hosted by Thurl Harris, James Grannerman, PhD is a Professor of Molecular Medicine and Genetics and Internal Medicine, Director, Center for Integrative Metabolic and Endocrine Research(CIMER), Wayne State University Research Focus: ...
Mar 29 Pharmacology Seminar by Kevin Foskett
3/29/2018
[Pinn Hall 1-17] Hosted by Adi Narahari/Pharm Students Research Description The Foskett lab is interested, most generally, in membrane transport and cell signaling. The techniques we employ in the lab span the spectrum from biophysical to molecular....
Mar 28 Dissertation Defense Seminar by Vlad Serbulea
3/28/2018
[Pinn 5023] Dissertation Defense Seminar by Vlad Serbulea Mentored by: Norbert Leitinger, Professor of Pharmacology
Mar 22 Pharmacology Seminar by Valentin Cracan
3/22/2018
[Pinn 1-17] Hosted by Bimal Desai Valentin Cracan is an Assistant in Molecular Biology, Mootha Lab, Molecular Biology Simches Research Center Boston, MA Mootha Lab Research focuses on mitochondria, often referred to as the powerhouse of the cell. T...
Mar 20 Pharm 9003 Class Lecture by Carrie Jones, PhD
3/20/2018
[Pinn 5023] Hosted by Spring 2018 Pharm 9003 Class, Beth Sharlow, PhD and John Lazo, Phd Carrie Jones, PhD, is an Assistant Professor, Pharmacology and Director of BCarrie Jones received her B.S. in Biology from Indiana University and further complet...